BACTIVTM Phase 3 SOLO II Trial Results Published In The Journal Clinical Infectious Diseases

By: via Benzinga
The Medicines Company (NASDAQ: MDCO) today announced the publication of the results from the SOLO II Phase 3 clinical trial of ORBACTIV ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.